Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06). CONCLUSIONS: Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent trials have studied higher dosages of omega-3 fatty acids, reporting a cardiovascular benefit in 2 trials of purified EPA. 10,11”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [11]
In the citing paper
“O3CA lowered non-HDL-C by 6% and apo B by 2%, 41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“With regard to O3CA, the 2-g/d dose examined in the ESPRIT trial (Epanova Combined with a Statin in Patients with Hypertriglyceridemia to Reduce Non-HDL Cholesterol; ≈1.5 g/d EPA+DHA) reduced triglycerides by 9% versus 15% with 4 g/d.41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“High‐dose eicosapentaenoic ethyl ester combined with baseline statins can lead to a remarkable decline in first and recurrent events in high‐risk patients with hypertriglyceridemia. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
In the citing paper
“Conversely, patients with hypertriglyceridemia treated with a medium‐to‐high dose of icosapent ethyl were less likely to develop ischemic events, including CVD death. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
126 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Martin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kwiterovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013) · JAMA · doi:10.1001/jama.2013.280532 · Cited by 883
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Self-citationEffects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
Cited by
Items 401–500 of 1,052
Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review
Claessen, B. E. P. M., Guedeney, P., Gibson, C. M., Angiolillo, D. J., Cao, D., Lepor, N. E., & Mehran, R. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018897 · Cited by 71
Essential Fatty Acids as Biomedicines in Cardiac Health
Balta, I., Ştef, L., Peț, I., Iancu, T., Stef, D. S., & Corcionivoschi, N. (2021) · Biomedicines · doi:10.3390/biomedicines9101466 · Cited by 81
Vegan nutrition: a preliminary guide for health professionals
Koeder, C., & Pérez-Cueto, F. J. A. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2107997 · Cited by 80
Nutritional Strategies for the Management of Type 2 Diabetes Mellitus: A Narrative Review
Minari, T. P., Tácito, L. H. B., Yugar, L. B. T., Ferreira‐Melo, S. E., Manzano, C. F., Pires, A. C., Moreno, H., Vilela-Martin, J. F., Cosenso‐Martin, L. N., & Yugar‐Toledo, J. C. (2023) · Nutrients · doi:10.3390/nu15245096 · Cited by 103
Do patients benefit from omega-3 fatty acids?
Sherratt, S. C. R., Mason, R. P., Libby, P., Steg, P. G., & Bhatt, D. L. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad188 · Cited by 79
Self-citationNdumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 153
Self-citationMacrophage fatty acid metabolism and atherosclerosis: The rise of PUFAs
Ménégaut, L., Jalil, A., Thomas, C., & Masson, D. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.10.002 · Cited by 68
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Self-citationEffect of Nutrient and Micronutrient Intake on Chylomicron Production and Postprandial Lipemia
Desmarchelier, C., Borel, P., Lairon, D., Maraninchi, M., & Valéro, R. (2019) · Nutrients · doi:10.3390/nu11061299 · Cited by 75
Intracranial Atherosclerosis Treatment
Flusty, B., de Havenon, A., Prabhakaran, S., Liebeskind, D. S., & Yaghi, S. R. (2020) · Stroke · doi:10.1161/strokeaha.119.028528 · Cited by 67
Ruscica, M., Penson, P. E., Ferri, N., Sirtori, C. R., Pirro, M., Mancini, G. B. J., Sattar, N. A., Toth, P. P., Sahebkar, A., Lavie, C. J., et al. (2021) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2021.06.010 · Cited by 73
Effects of fatty acids on T cell function: role in atherosclerosis
Reilly, N. A., Lutgens, E., Kuiper, J., Heijmans, B. T., & Jukema, J. W. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00582-9 · Cited by 68
Dynamic metabolism of endothelial triglycerides protects against atherosclerosis in mice
Boutagy, N. E., Gámez-Méndez, A. M., Fowler, J. W., Zhang, H., Chaube, B., Esplugues, E., Kuo, A., Lee, S., Horikami, D., Zhang, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170453 · Cited by 67
Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids
Weinberg, R. L., Brook, R. D., Rubenfire, M., & Eagle, K. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.060 · Cited by 63
Iqbal, Z., Ho, J. H., Adam, S., France, M. W., Syed, A. A., Neely, D., Rees, A., Khatib, R., Cegla, J., Byrne, C. D., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.09.008 · Cited by 66
Lamon‐Fava, S., So, J., Mischoulon, D., Ziegler, T. R., Dunlop, B. W., Kinkead, B. L., Schettler, P. J., Nierenberg, A. A., Felger, J. C., Maddipati, K. R., et al. (2020) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102219 · Cited by 66
Lipoproteins in chronic kidney disease: from bench to bedside
Speer, T., Ridker, P. M., von Eckardstein, A., Schunk, S. J., & Fliser, D. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1050 · Cited by 69
Liu, Q. K. (2021) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2021.05.007 · Cited by 60
New Therapies for Lowering Triglyceride-Rich Lipoproteins
Rosenson, R. S., Shaik, A., & Song, W. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.051 · Cited by 62
The ACSL4 Network Regulates Cell Death and Autophagy in Diseases
Chen, F., Kang, R., Liu, J., & Tang, D. (2023) · Biology · doi:10.3390/biology12060864 · Cited by 74
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Lorenzatti, A. J., & Toth, P. P. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.06 · Cited by 72
Combating Inflammation in Cardiovascular Disease
Sethwala, A., Goh, I. Y., & Amerena, J. V. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.09.003 · Cited by 69
Hypertriglyceridemia: A Neglected Risk Factor for Ischemic Stroke?
Liang, H., Zhang, Q., Hu, Y., Liu, G., & Qi, R. (2022) · Journal of Stroke · doi:10.5853/jos.2021.02831 · Cited by 85
Bay, B., Tanner, R., Gao, M., Oliva, A., Sartori, S., Vogel, B., Gitto, M., Smith, K. F., Muro, F. M. D., Hooda, A., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf196 · Cited by 82
Dyslipidemia in nonalcoholic fatty liver disease
Amor, A. J., & Perea, V. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000464 · Cited by 74
Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial)
Ramirez, J. L., Gasper, W. J., Khetani, S. A., Zahner, G. J., Hills, N. K., Mitchell, P. T., Sansbury, B. E., Conte, M. S., Spite, M. R., & Grenon, S. M. (2019) · Journal of Surgical Research · doi:10.1016/j.jss.2019.01.038 · Cited by 63
Pal, A., Al‐Shaer, A. E., Guesdon, W., Torres, M. J., Armstrong, M., Quinn, K. D., Davis, T., Reisdorph, N. A., Neufer, P. D., Spangenburg, E. E., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000830r · Cited by 68
Barkas, F., Nomikos, T., Liberopoulos, E. N., & Panagiotakos, D. B. (2020) · Nutrients · doi:10.3390/nu12082436 · Cited by 74
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61
Alexander, L., Christensen, S. M., Richardson, L., Ingersoll, A. B., Burridge, K., Golden, A., Karjoo, S., Cortez, D., Shelver, M., & Bays, H. E. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2021.100005 · Cited by 61
“In patients at risk for atherosclerotic cardiovascular disease and elevated triglyceride levels, prescription dose omega-3 fatty acids (4 g per day of eicosapentaenoic acid) can reduce triglyceride levels and reduce the risk of cardiovascular disease [23].”
BackgroundGaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.035 · Cited by 61
Self-citationTriglycerides and residual risk
Vallejo‐Vaz, A. J., Corral, P., Schreier, L. E., & Ray, K. K. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000530 · Cited by 65
Lipid lowering therapy in cardiovascular disease: From myth to molecular reality
Mourikis, P., Zako, S., Dannenberg, L., Nia, A. M., Heinen, Y., Busch, L., Richter, H., Hohlfeld, T., Zeus, T., Kelm, M., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107592 · Cited by 63
Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis
Lok, C. E., Farkouh, M., Hemmelgarn, B. R., Moist, L. M., Polkinghorne, K. R., Tomlinson, G., Tam, P., Tonelli, M., & Udell, J. A. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2513032 · Cited by 60
Nordestgaard, L. T., Christoffersen, M., Afzal, S., Nordestgaard, B. G., Tybjærg-Hansen, A., & Frikke-Schmidt, R. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa269 · Cited by 60
Chevalier, L., Vachon, A., & Plourde, M. (2020) · Journal of Nutrition · doi:10.1093/jn/nxaa458 · Cited by 69
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19
Talasaz, A. H., Sadeghipour, P., Aghakouchakzadeh, M., Dreyfus, I., Kakavand, H., Ariannejad, H., Gupta, A., Madhavan, M. V., Tassell, B. W. V., Jiménez, D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.021 · Cited by 65
Self-citationCirculating trimethylamine N-oxide levels following fish or seafood consumption
Wang, Z., Tang, W. H. W., O’Connell, T. F., Garcia, E., Jeyarajah, E. J., Li, X. S., Jia, X., Weeks, T. L., & Hazen, S. L. (2022) · European Journal of Nutrition · doi:10.1007/s00394-022-02803-4 · Cited by 74
Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association
Javed, F., Hegele, R. A., Garg, A., Patni, N., Gaudet, D., Williams, L., Khan, M., Li, Q., & Ahmad, Z. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2025.03.013 · Cited by 60
Cholesterol Lowering and Prevention of Stroke: An Overview
Hackam, D. G., & Hegele, R. A. (2019) · Stroke · doi:10.1161/strokeaha.118.023167 · Cited by 72
Alexopoulos, A., Qamar, A., Hutchins, K., Crowley, M. J., Batch, B. C., & Guyton, J. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1136-3 · Cited by 75
Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors
Wójcik, C., & Warden, B. A. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1219-4 · Cited by 71
Dietary and Pharmacological Fatty Acids and Cardiovascular Health
Wu, H., Xu, L., & Ballantyne, C. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz174 · Cited by 59
Self-citationShen, S., Gong, C., Jin, K., Zhou, L., Xiao, Y., & Ma, L. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.809311 · Cited by 59
Rizos, E. C., Markozannes, G., Tsapas, A., Mantzoros, C. S., & Ntzani, E. E. (2021) · Heart · doi:10.1136/heartjnl-2020-316780 · Cited by 39
Verma, S., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Dhingra, N. K., Ketchum, S. B., Juliano, R. A., Jiao, L., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.056290 · Cited by 59
Self-citationMa, B., Xiao, Y., Lv, Q., Li, G., Wang, Y., & Fu, G. (2022) · Advanced Materials · doi:10.1002/adma.202206129 · Cited by 67
Updates in Drug Treatment of Severe Hypertriglyceridemia
Gouni-Berthold, I., Schwarz, J., & Berthold, H. K. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01140-z · Cited by 59
“Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) can decrease TG levels by ~ 20% [8].”
BackgroundNovel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease
Zheng, W. C., Chan, W., Dart, A., & Shaw, J. A. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad074 · Cited by 59
Brieger, D. B., Cullen, L., Briffa, T. G., Zaman, S. J., Scott, I. A., Papendick, C., Bardsley, K., Baumann, A. A. W., Bennett, A., Clark, R. A., et al. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.02.102 · Cited by 74
Rossato, L. T., Schoenfeld, B. J., & de Oliveira, E. P. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2019.01.001 · Cited by 69
Toth, P. P., Philip, S., HULL, M. L., & Granowitz, C. B. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.03.028 · Cited by 64
Self-citationRecent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids
Kris‐Etherton, P. M., Richter, C. K., Bowen, K. J., Skulas‐Ray, A. C., Jackson, K. H., Petersen, K. S., & Harris, W. S. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-3-171 · Cited by 69
McReynolds, C. B., Morisseau, C. H. P., Wagner, K. M., & Hammock, B. D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50621-6_5 · Cited by 69
Targeting Inflammation to Reduce Residual Cardiovascular Risk
Ajala, O. N., & Everett, B. M. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00883-3 · Cited by 65
Triglyceride lowering by omega-3 fatty acids: a mechanism mediated by N-acyl taurines
Bornfeldt, K. E. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147558 · Cited by 58
“Research on the omega-3 fatty acids eicosapentaenoic acid (C20:5; EPA) and docosahexaenoic acid (C22:6; DHA) has intensified after the REDUCE-IT (NCT01492361) cardiovascular outcome trial revealed that purified EPA ethyl ester (icosapent ethyl) had protective effects in statin-treated individuals (7).”
BackgroundInfluentialPosicionamento sobre o Consumo de Gorduras e Saúde Cardiovascular – 2021
Izar, M. C. D. O., Lottenberg, A. M., Giraldez, V. Z. R., Santos, R. D., Machado, R. M., Bertolami, A., Assad, M. H. V., Saraiva, J. F. K., Faludi, A. Á., Moreira, A. S. B., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201340 · Cited by 142
Revisiting secondary prevention in coronary heart disease
Sigamani, A., & Gupta, R. (2022) · Indian Heart Journal · doi:10.1016/j.ihj.2022.11.011 · Cited by 87
Javaid, M., Kadhim, K., Bawamia, B., Cartlidge, T., Farag, M., & Alkhalil, M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032390 · Cited by 58
“5 This reduction was not proportionate to the change in patients’ lipid profile and suggested pleotropic effects of icosapent ethyl beyond its triglyceride-lowering effects.”
Advancements in risk stratification and management strategies in primary cardiovascular prevention
Barkas, F., Şener, Y. Z., Golforoush, P. A., Kheirkhah, A., Rodríguez‐Sánchez, E., Novák, J., Apellániz-Ruiz, M., Akyea, R. K., Bianconi, V., Ceasovschih, A., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117579 · Cited by 65
Goldberg, R. B., Stone, N. J., & Grundy, S. M. (2020) · Diabetes Care · doi:10.2337/dci19-0036 · Cited by 58
Mach, F., Visseren, F. L. J., Cater, N. B., Salhi, N., Soronen, J., Ray, K. K., Delgado, V., Jukema, J. W., Laufs, U., Zamorano, J.-L., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.07.001 · Cited by 57
Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050276 · Cited by 57
Self-citationFan, W., Philip, S., Granowitz, C. B., Toth, P. P., & Wong, N. D. (2019) · Diabetes Care · doi:10.2337/dc19-0501 · Cited by 62
Self-citationTriglycerides and ASCVD risk reduction: recent insights and future directions
Hussain, A., Ballantyne, C. M., Saeed, A., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00846-8 · Cited by 57
Self-citationKothapalli, K. S. D., Park, H. G., & Brenna, J. T. (2020) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2020.102183 · Cited by 57
Welty, F. K., Schulte, F., Alfaddagh, A., Elajami, T. K., Bistrian, B. R., & Hardt, M. (2021) · The FASEB Journal · doi:10.1096/fj.202002471r · Cited by 59
Venn-Watson, S. K., & Butterworth, C. N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268778 · Cited by 58
Galimberti, F., Casula, M., & Olmastroni, E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106873 · Cited by 78
Cucchi, D., Camacho‐Muñoz, D., Certo, M., Niven, J., Smith, J., Nicolaou, A., & Mauro, C. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz208 · Cited by 68
Dietary n-3 polyunsaturated fatty acids, fish intake and healthy ageing
García‐Esquinas, E., Ortolá, R., Banegas, J. R., López‐García, E., & Rodríguez‐Artalejo, F. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyz196 · Cited by 59
Masana, L., Ibarretxe, D., & Plana, N. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01326-w · Cited by 54
Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
Theofilis, P., Vordoni, A., Koukoulaki, M., Vlachopanos, G., & Kalaitzidis, R. (2021) · American Journal of Nephrology · doi:10.1159/000518456 · Cited by 64
Jerab, D., Blangero, F., da Costa, P. C. T., Alves, J. L. D. B., Kéfi, R., Jamoussi, H., Morio, B., & Eljaafari, A. (2025) · Nutrients · doi:10.3390/nu17071253 · Cited by 74
Toth, P. P., Fazio, S., Wong, N. D., HULL, M. L., & Nichols, G. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13921 · Cited by 69
New Trends in Dyslipidemia Treatment
Jang, A. Y., Lim, S., Jo, S.-H., Han, S. H., & Koh, K. K. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-1037 · Cited by 52
Casula, M., Olmastroni, E., Gazzotti, M., Galimberti, F., Zambon, A., & Catapano, A. L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105060 · Cited by 54
Contemporary Management of Dyslipidemia
Ferraro, R., Leucker, T. M., Martin, S. S., Banach, M., Jones, S. R., & Toth, P. P. (2022) · Drugs · doi:10.1007/s40265-022-01691-6 · Cited by 66
Target Populations for Novel Triglyceride-Lowering Therapies
Nordestgaard, A. T., Tybjærg-Hansen, A., Mansbach, H., Kersten, S., Nordestgaard, B. G., & Rosenson, R. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.035 · Cited by 54
The Role of Omega-3 and Omega-6 Polyunsaturated Fatty Acid Supplementation in Human Health
Gutierres, D., Pacheco, R., & Reis, C. P. (2025) · Foods · doi:10.3390/foods14193299 · Cited by 71
Zhao, J. V., & Schooling, C. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1293-x · Cited by 59
Klingel, S. L., Metherel, A. H., Irfan, M., Rajna, A., Chabowski, A., Bazinet, R. P., & Mutch, D. M. (2019) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz234 · Cited by 54
Lipoprotein metabolism in familial hypercholesterolemia
Chemello, K., García‐Nafría, J., Gallo, A., Martín, C., Lambert, G. C., & Blom, D. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100062 · Cited by 65
O’Fee, K., Deych, E., Ciani, O., & Brown, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5726 · Cited by 59
Grundy, S. M., & Stone, N. J. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0911 · Cited by 58
Bioactive Lipid Signaling in Cardiovascular Disease, Development, and Regeneration
Wasserman, A. H., Venkatesan, M., & Aguirre, A. (2020) · Cells · doi:10.3390/cells9061391 · Cited by 50
Zhang, T., Zhao, J. V., & Schooling, C. M. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2020.103189 · Cited by 61
Recurrent Events in Cardiovascular Trials
Gregson, J., Stone, G. W., Bhatt, D. L., Packer, M., Anker, S. D., Zeller, C., Redfors, B., & Pocock, S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.07.024 · Cited by 59
Self-citationPreventive Cardiology as a Subspecialty of Cardiovascular Medicine
Shapiro, M. D., Maron, D. J., Morris, P. B., Kosiborod, M., Sandesara, P. B., Virani, S. S., Khera, A., Ballantyne, C. M., Baum, S. J., Sperling, L. S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1016 · Cited by 56
Self-citationApolipoprotein C-II: the re-emergence of a forgotten factor
Wolska, A., Reimund, M., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000680 · Cited by 52
The Effect of Blood Lipids on the Left Ventricle
Aung, N., Sanghvi, M. M., Piechnik, S. K., Neubauer, S., Munroe, P. B., & Petersen, S. E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.583 · Cited by 60
Atherosclerosis is a major human killer and non-resolving inflammation is a prime suspect
Fredman, G., & MacNamara, K. C. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab309 · Cited by 64
Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay
Wilkinson, M. J., & Shapiro, M. D. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.319983 · Cited by 64
Predicting Risk for Incident Heart Failure With Omega-3 Fatty Acids
Block, R., Liu, L., Herrington, D. M., Huang, S., Tsai, M. Y., O’Connell, T. D., & Shearer, G. C. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.03.008 · Cited by 57
Karwatowska-Prokopczuk, E., Tardif, J.-C., Gaudet, D., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Amour, E. S., Alexander, V. J., Xia, S., et al. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.06.005 · Cited by 51
Self-citationFreeman, A. M., Raman, S. V., Aggarwal, M., Maron, D. J., Bhatt, D. L., Parwani, P. J., Osborne, J., Earls, J. P., Min, J. K., Bax, J. J., et al. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.10.021 · Cited by 59
Self-citationLipid lowering combination therapy: From prevention to atherosclerosis plaque treatment
Masana, L., Plana, N., Andreychuk, N., & Ibarretxe, D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106738 · Cited by 59
The Interplay Between Immunity, Inflammation and Endothelial Dysfunction
Chee, Y. J., Dalan, R., & Cheung, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041708 · Cited by 70
Djuricic, I. D., & Calder, P. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01363-2 · Cited by 75
Dyslipidemia Profiles in Patients with Peripheral Artery Disease
Aday, A. W., & Everett, B. M. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1129-5 · Cited by 63
Metadata
- Authors
- Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, J.-C., & Ballantyne, C. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B.); FACT (French Alliance for Cardiovascular Trials), Département Hospitalo-Universitaire FIRE (Fibrose, Inflammation, and Remodeling), Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Université Paris-Diderot, INSERM Unité 1148, Paris (P.G.S.); National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the Department of Medicine, University of Maryland...
- University of Maryland, Baltimore (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 11-22
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899669642
- Cited by
- 3,317
- References
- 47
- Citations by year
- 2026: 327 · 2025: 354 · 2024: 377 · 2023: 430 · 2022: 427 · 2021: 481 · 2020: 518 · 2019: 362
- FWCI
- 286.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amarin
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- icosapent ethyl, eicosapentaenoic acid ethyl ester, hypertriglyceridemia, cardiovascular risk reduction, ischemic events, cardiovascular mortality, myocardial infarction, stroke, coronary revascularization, unstable angina, statin therapy, omega-3 fatty acids, secondary prevention, triglyceride-lowering therapy, LDL cholesterol, diabetes mellitus
- MeSH terms
- Aged, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Triglycerides, Eicosapentaenoic Acid, Hypertriglyceridemia, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.